undamentalytics Newsletter
Sign in

Janux Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Janux Therapeutics, Inc. had total assets of $1.00bn, total liabilities of $44.7m and shareholders' equity of $957m. It held $52.3m in cash against $0 of debt: net cash of $52.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents83651194315228
Receivables8000—00
Total current assets163773323491,034976983
Total assets163803643801,0621,0021,008
Accounts payable0222453
Deferred revenue (current)25520035
Total current liabilities3131713172560
Total debt0000000
Total liabilities9134336394580
Shareholders' equity−153663213441,023957928
Non-controlling interests and other (assets − liabilities − equity)22——————
Net debt (negative = net cash)−8−36−51−19−431−52−28
Shares outstanding1m—42m46m59m60m61m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CRSP vs JANXABEO vs JANXJANX vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Janux Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Janux Therapeutics, Inc.